Log in | Register

Should we rely on trials with disease- rather than patient-oriented endpoints?Open access

Harm-Jan de Grooth| Jean-Jacques Parienti| Heleen M. Oudemans-van Straaten
What's New in Intensive Care
Volume 44, Issue 4 / April , 2018

Pages 464 - 466

No abstract available.

References

  1. Bucher HC, Guyatt GH, Cook DJ, Evidence-Based Medicine Working Group et al (1999) Users’ guides to the medical literature: XIX. Applying clinical trial results A. How to use an article measuring the effect of an intervention on surrogate end points. JAMA 282:771–778. doi:10.1001/jama.282.8.771
    • View reference on publisher's website
    • View reference on PubMed
  2. Tibby SM (2010) Does PELOD measure organ dysfunction…and is organ function a valid surrogate for death? Intensive Care Med 36:4–7. doi:10.1007/s00134-009-1712-0
  3. Kellum JA, Zarbock A, Nadim MK (2017) What endpoints should be used for clinical studies in acute kidney injury? Intensive Care Med. doi:10.1007/s00134-017-4732-1
  4. Fleming TR, DeMets DL (1996) Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125:605–613
    • View reference on publisher's website
    • View reference on PubMed
  5. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1998) ICH harmonized tripartite guideline: statistical principles for clinical trials E9
  6. Rubenfeld GD (2003) Surrogate measures of patient-centered outcomes in critical care. In: Angus DC, Carlet J (eds) Surviving intensive care. Springer, Berlin, pp 169–180
  7. Echt DS, Liebson PR, Mitchell LB et al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med 324:781–788. doi:10.1056/NEJM199103213241201
    • View reference on publisher's website
    • View reference on PubMed
  8. Stapleton RD, Wang BM, Hudson LD et al (2005) Causes and timing of death in patients with ARDS. Chest 128:525–532. doi:10.1378/chest.128.2.525
    • View reference on publisher's website
    • View reference on PubMed
  9. Afshari A, Brok J, Møller AM, Wetterslev J (2010) Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults. Cochrane Database Syst Rev. doi:10.1002/14651858.CD002787.pub2
  10. Buyse M, Molenberghs G, Burzykowski T et al (2000) The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1:49–67. doi:10.1093/biostatistics/1.1.49
    • View reference on publisher's website
    • View reference on PubMed
  11. Daniels MJ, Hughes MD (1997) Meta-analysis for the evaluation of potential surrogate markers. Stat Med 16:1965–1982. doi:10.1002/(SICI)1097-0258(19970915)16:17<1965:AID-SIM630>3.0.CO;2-M
    • View reference on publisher's website
    • View reference on PubMed
  12. de Grooth H-J, Geenen IL, Girbes AR et al (2017) SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis. Crit Care 21:38. doi:10.1186/s13054-017-1609-1
    • View reference on publisher's website
    • View reference on PubMed
  13. Freedman LS, Graubard BI, Schatzkin A (1992) Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11:167–178
    • View reference on publisher's website
    • View reference on PubMed
  14. Cleophas TJ, Zwinderman AH (2012) Validating surrogate endpoints of clinical trials. In: Statistics applied to clinical studies. Springer, Berlin, pp 569–578
  15. Parast L, McDermott MM, Tian L (2016) Robust estimation of the proportion of treatment effect explained by surrogate marker information. Stat Med 35:1637–1653. doi:10.1002/sim.6820
    • View reference on publisher's website
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement